Company: MIRM
Filing Date: 2025-08-12
Form Type: S-3ASR
Source: 0001193125-25-178937
Chunk: 35

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-3ASR
Chunk 35
---
. We have described the rights of holders and street name investors above. Unless we provide otherwise in the applicable prospectus supplement, a global security will terminate when the following special situations occur:

| • |     | if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for 
 that global security and we do not appoint another institution to act as depositary within 90 days;             |

| • |     | if we notify any applicable trustee that we wish to terminate that global security; or |

| • |     | if an event of default has occurred with regard to securities represented by that global security and has not 
 been cured or waived.                                                                                         |

27

The applicable prospectus supplement may also list additional situations for terminating a
global security that would apply only to the particular series of securities covered by the applicable prospectus supplement. When a global security terminates, the depositary, and neither we nor any applicable trustee, is responsible for deciding
the names of the institutions that will be the initial direct holders.

28

PLAN OF DISTRIBUTION We may sell the securities covered hereby from time to time pursuant to underwritten public offerings, direct sales to the public, negotiated transactions, block trades or a combination of these methods. A distribution of these securities offered by this prospectus may also be effected through the issuance of derivative securities, including without limitation, warrants. We may sell the securities to or through one or more underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions:

| • |     | at a fixed price or prices, which may be changed; |

| • |     | at market prices prevailing at the time of sale; |

| • |     | at prices related to such prevailing market prices; or |

| • |     | at negotiated prices. |

We may also sell equity securities covered by this registration statement in an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price, either:

| • |     | on or through the facilities of the Nasdaq Global Market or any other securities exchange or quotation or trading 
 service on which such securities may be listed, quoted or traded at the time of sale; and/or                      |

| • |     | to or through a market maker other than on the Nasdaq Global Market or such other